Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Their mission is to develop innovative therapies that make a difference in the lives of patients, with a focus on high value potential biologics targeting dysregulated inflammation. Their lead asset is AVTX-009, an anti-IL-1β monoclonal antibody, which is currently in Phase 2 trials for hidradenitis suppurativa. The company emphasizes teamwork, passion for science, and dedication to patients, with a strong leadership team and strategic partnerships with companies like Janssen and Merck.
Industries
Nr. of Employees
small (1-50)
Products
AVTX-009
Humanized IgG4 monoclonal antibody that binds and neutralizes interleukin-1β; under clinical evaluation (Phase 2) for hidradenitis suppurativa and being developed for multiple immune-mediated diseases.
LOTUS Phase 2 clinical trial (AVTX-009 in hidradenitis suppurativa)
Randomized, double-blind, placebo-controlled Phase 2 study evaluating two dose regimens of an IL-1β neutralizing antibody in ~220 adults with moderate to severe hidradenitis suppurativa; primary endpoint HiSCR75 at Week 16.
Flexichamber (prescription device)
Medical device offered as a prescription device (patient instructions and adverse event reporting information provided).
Millipred (prescription medication)
Prescription corticosteroid tablets (U.S. prescribing information available on linked drug information resource).
Poly-Vi-Flor and Tri-Vi-Flor (prescription dietary supplements)
Vitamin and fluoride supplements for infants and children in oral suspension and chewable tablet formulations; labeling referenced in linked drug information resource.
AVTX-009
Humanized IgG4 monoclonal antibody that binds and neutralizes interleukin-1β; under clinical evaluation (Phase 2) for hidradenitis suppurativa and being developed for multiple immune-mediated diseases.
LOTUS Phase 2 clinical trial (AVTX-009 in hidradenitis suppurativa)
Randomized, double-blind, placebo-controlled Phase 2 study evaluating two dose regimens of an IL-1β neutralizing antibody in ~220 adults with moderate to severe hidradenitis suppurativa; primary endpoint HiSCR75 at Week 16.
Flexichamber (prescription device)
Medical device offered as a prescription device (patient instructions and adverse event reporting information provided).
Millipred (prescription medication)
Prescription corticosteroid tablets (U.S. prescribing information available on linked drug information resource).
Poly-Vi-Flor and Tri-Vi-Flor (prescription dietary supplements)
Vitamin and fluoride supplements for infants and children in oral suspension and chewable tablet formulations; labeling referenced in linked drug information resource.
Services
Partnerships and licensing
In-licensing and out-licensing of product candidates and execution of strategic alliances to advance clinical programs.
Patient engagement and clinical study support
Provision of patient-facing information, advocacy engagement, and guidance on clinical trial eligibility and access.
Regulatory and quality program management
Global regulatory planning, submission support, and quality assurance oversight to support development programs.
Adverse event reporting and pharmacovigilance contact
Channels for reporting suspected adverse reactions and processes for safety reporting to regulatory authorities.
Partnerships and licensing
In-licensing and out-licensing of product candidates and execution of strategic alliances to advance clinical programs.
Patient engagement and clinical study support
Provision of patient-facing information, advocacy engagement, and guidance on clinical trial eligibility and access.
Regulatory and quality program management
Global regulatory planning, submission support, and quality assurance oversight to support development programs.
Adverse event reporting and pharmacovigilance contact
Channels for reporting suspected adverse reactions and processes for safety reporting to regulatory authorities.
Expertise Areas
- Clinical trial management
- Dermatology and inflammatory disease therapeutics
- Monoclonal antibody and fusion protein development
- Biomarker-guided drug development
Key Technologies
- Monoclonal antibody therapeutics
- Fusion protein therapeutics
- Biomarker-based patient stratification
- Randomized double-blind placebo-controlled trial design